A retrospective, observational, longitudinal study assessing mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma
Latest Information Update: 07 Oct 2021
Price :
$35 *
At a glance
- Drugs Mepolizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- 07 Oct 2021 New trial record